TP53 and breast carcinoma: To understand how treatment with either SSO or BMS-309403 decreased proliferation, migration and invasion capabilities of breast cancer cells while still maintaining cell viability we assessed the expression levels of markers associated with cell senescence (DEC1, DcR1 and DcR2) and markers associated with cell cycle arrest (p21cip1, p16 and p53).